Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments

A technology of ganoderma acid and superantigen, which is applied in the direction of antitumor drugs, medical preparations containing active ingredients, drug combinations, etc., can solve problems such as tumor drug resistance, achieve low cytotoxicity, good application prospects, and reduce side effects effect of possibility

Inactive Publication Date: 2012-05-09
李仲娟 +1
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the biggest problem in cancer chemotherapy is drug resistance formed by tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments
  • Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments
  • Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] use 3 H method was used to determine the inhibitory effect of U-937, Ramos, K562, Raji, THP-1 tumor cells. logarithmic phase cells by 10 4 Inoculate each well in a 96-well round-bottom culture plate, 200 μl per well, parallel 3 wells, add the same amount of culture medium to the control group, add ganoderma acid G with concentrations of 0, 30, 100, and 300 μg / ml respectively, and place at 37 °C 5%CO 2 Incubate for 72 hours in the incubator, add 6 hours before counting 3 H, and then count the growth of tumor cells and make a graph.

Embodiment 2

[0039] KB-A-1 cells in logarithmic phase 10 6 / ml concentration, 0.2ml / inoculate underarms of nude mice, grow in nude mice SPF environment for 15 days, separate solid tumors, inoculate left and right armpits of experimental nude mice under sterile conditions, and treat with intraperitoneal injection of drugs after 5 days, according to cisplatin (Cisplatin DDP) group and cisplatin plus ganoderma acid G group were treated. 5 days as a course of treatment, a total of 2 courses of treatment. The nude mice were sacrificed 6 days after drug withdrawal, and the solid tumors were weighed to calculate the tumor inhibition rate.

[0040] Tumor inhibition rate (%)=[(average weight of solid tumors in the control group-average weight of solid tumors in the administration group) / average weight of solid tumors in the control group]×100

Embodiment 3

[0042] use 3 Determination of KB-A-1, U-937, Ramos, K562, Raji, THP-1, A20, Hela and CD4 by H method + Toxic effect of normal human T cells, logarithmic phase cells by 10 4Inoculate each well in a 96-well round-bottom culture plate, 200 μl per well, parallel 3 wells, add the same amount of culture medium to the control wells, stimulate with 100 μg / ml ganoderma acid G, and place at 37°C in 5% CO 2 Incubate for 72 hours in the incubator, add 6 hours before counting 3 H, and then calculate the inhibitory rate of the drug on the cells, and plot it with the half inhibitory concentration of the cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel purpose of ganoderic acid, in particular to application of the ganoderic acid G in various tumour treatments. The ganoderic acid G disclosed by the invention comprises various preparations including solid type preparations of troches, capsules and the like, ointment, pasting agents, injections and the like, which can be prepared by adopting a conventional method in a pharmaceutical field. The tumour treatment medicine provided by the invention, namely the ganoderic acid G, has the function of directly inhibiting tumour cell proliferation under small dose; at this time, the ganoderic acid G has low toxic effect on normal tissue cells; and the effect of further treating tumours is realized after adding super-antigen. The application of the ganoderic acid G as the immune synergist and the super-antigen dependent therapeutic medicine in the tumour treatments disclosed by the invention has the obvious advantages and the technical progresses that: when the ganoderic acid G is united with the super-antigen, the function of killing and wounding a wide variety of tumour cells in extracorporeal and esoteric experiments can be effectively played.

Description

technical field [0001] The present invention relates to a new application of ganodermic acid, in particular to a new application of ganoderic acid G (Ganoderic acid G). Background technique [0002] Ganoderma lucidum is a treasure in the treasure house of traditional Chinese medicine. There have been many legends about Ganoderma lucidum since ancient times. In these mythical and superstitious legends, Ganoderma lucidum is regarded as "immortal grass" and "auspicious grass", and it is regarded as a symbol of "good luck". In ancient Chinese literature, "Shen Nong's Materia Medica" from around the first century BC, "Baopuzi" by Ge Hong in the Eastern Jin Dynasty, "Xinxiu Materia Medica" by Su Jing in the Tang Dynasty, "Shen Nong's Materia Medica" by Tao Hongjing in the Liang Dynasty, and "Famous Physicians" "Records" and "Compendium of Materia Medica" by Li Shizhen of the Ming Dynasty further supplemented and revised the exposition of Ganoderma lucidum on the basis of "Shen No...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P35/00A61P35/02
Inventor 李仲娟杨朝令
Owner 李仲娟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap